课题基金 / 基金详情

Statistical and Ethical Implications of Pimavanserin Drug Trials Published with Unexplained or Missing Datasets on Parkinson's Disease

发表的帕金森病数据集不明或缺失的匹马范色林药物试验的统计和伦理意义

批准号：

449377

负责人：

Law Ka Long B

金额：

$1.27万

依托单位：

University of Western Ontario

依托单位国家：

加拿大

项目类别：

Studentship Programs

财政年份：

2020

资助国家：

加拿大

项目状态：

已结题

起止时间：

2020-12-01 至 2021-12-01

来源：

https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=449377&lang=en

关键词：

Clinical Trials Drug Efficacy Drug Safety Health Policy Parkinson'S Disease Pimavanserin Quantitative Methodology

项目摘要

项目成果

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

Pimavanserin is a drug that has been approved by the Food and Drug Administration (FDA) to offset Parkinson's Disease Psychosis (PDP), a side effect of common Parkinson's Disease (PD) medications. However, it has not been approved in Canada. It was origin

期刊论文(0)

专著(0)

科研奖励(0)

会议论文